Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

Background In REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial), icosapent ethyl (IPE) versus placebo) reduced cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina requiring hospitalization, but was associated with i...

Full description

Bibliographic Details

Published in:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Main Authors:	Brian Olshansky, Deepak L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Peter R. Kowey, James A. Reiffel, Jean‐Claude Tardif, Christie M. Ballantyne, Mina K. Chung
Format:	Article
Language:	English
Published:	Wiley 2023-03-01
Subjects:	atrial fibrillation bleeding eicosapentaenoic acid icosapent ethyl prevention
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.121.026756